Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

JARID1 Histone Demethylases: Emerging Targets in Cancer.

Harmeyer KM, Facompre ND, Herlyn M, Basu D.

Trends Cancer. 2017 Oct;3(10):713-725. doi: 10.1016/j.trecan.2017.08.004. Epub 2017 Sep 12. Review.

PMID:
28958389
2.

The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Agarwal SK.

Endocr Relat Cancer. 2017 Oct;24(10):T119-T134. doi: 10.1530/ERC-17-0199. Review.

3.

Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.

Dreijerink KMA, Timmers HTM, Brown M.

Endocr Relat Cancer. 2017 Oct;24(10):T135-T145. doi: 10.1530/ERC-17-0281. Epub 2017 Aug 15. Review.

4.

Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish.

Scahill CM, Digby Z, Sealy IM, Wojciechowska S, White RJ, Collins JE, Stemple DL, Bartke T, Mathers ME, Patton EE, Busch-Nentwich EM.

PLoS Genet. 2017 Aug 14;13(8):e1006959. doi: 10.1371/journal.pgen.1006959. eCollection 2017 Aug.

5.

The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer.

Balch C, Ramapuram JB, Tiwari AK.

Front Pharmacol. 2017 May 19;8:267. doi: 10.3389/fphar.2017.00267. eCollection 2017. Review.

6.

Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.

Dreijerink KMA, Groner AC, Vos ESM, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, Lin CY, de Laat W, Rao PK, Long HW, Brown M.

Cell Rep. 2017 Mar 7;18(10):2359-2372. doi: 10.1016/j.celrep.2017.02.025.

7.

Histone demethylases and their roles in cancer epigenetics.

D'Oto A, Tian QW, Davidoff AM, Yang J.

J Med Oncol Ther. 2016;1(2):34-40.

8.

KDM5 lysine demethylases are involved in maintenance of 3'UTR length.

Blair LP, Liu Z, Labitigan RL, Wu L, Zheng D, Xia Z, Pearson EL, Nazeer FI, Cao J, Lang SM, Rines RJ, Mackintosh SG, Moore CL, Li W, Tian B, Tackett AJ, Yan Q.

Sci Adv. 2016 Nov 18;2(11):e1501662. doi: 10.1126/sciadv.1501662. eCollection 2016 Nov.

9.

The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation.

Brier AB, Loft A, Madsen JGS, Rosengren T, Nielsen R, Schmidt SF, Liu Z, Yan Q, Gronemeyer H, Mandrup S.

Nucleic Acids Res. 2017 Feb 28;45(4):1743-1759. doi: 10.1093/nar/gkw1156.

10.

Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.

Lin W, Francis JM, Li H, Gao X, Pedamallu CS, Ernst P, Meyerson M.

Cancer Biol Ther. 2016 Dec;17(12):1274-1281. doi: 10.1080/15384047.2016.1250986. Epub 2016 Nov 1.

11.

Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype.

Maggi EC, Trillo-Tinoco J, Struckhoff AP, Vijayaraghavan J, Del Valle L, Crabtree JS.

Oncogenesis. 2016 Aug 22;5(8):e257. doi: 10.1038/oncsis.2016.58.

12.

Kdm5/Lid Regulates Chromosome Architecture in Meiotic Prophase I Independently of Its Histone Demethylase Activity.

Zhaunova L, Ohkura H, Breuer M.

PLoS Genet. 2016 Aug 5;12(8):e1006241. doi: 10.1371/journal.pgen.1006241. eCollection 2016 Aug.

13.

Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.

Horton JR, Liu X, Gale M, Wu L, Shanks JR, Zhang X, Webber PJ, Bell JS, Kales SC, Mott BT, Rai G, Jansen DJ, Henderson MJ, Urban DJ, Hall MD, Simeonov A, Maloney DJ, Johns MA, Fu H, Jadhav A, Vertino PM, Yan Q, Cheng X.

Cell Chem Biol. 2016 Jul 21;23(7):769-81. doi: 10.1016/j.chembiol.2016.06.006. Epub 2016 Jul 14.

14.

RB1: a prototype tumor suppressor and an enigma.

Dyson NJ.

Genes Dev. 2016 Jul 1;30(13):1492-502. doi: 10.1101/gad.282145.116. Review.

15.

RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma.

Zhou D, Kannappan V, Chen X, Li J, Leng X, Zhang J, Xuan S.

Exp Mol Med. 2016 Jun 10;48:e238. doi: 10.1038/emm.2016.37.

16.

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.

Gale M, Sayegh J, Cao J, Norcia M, Gareiss P, Hoyer D, Merkel JS, Yan Q.

Oncotarget. 2016 Jun 28;7(26):39931-39944. doi: 10.18632/oncotarget.9539.

17.

Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies.

Kohno S, Kitajima S, Sasaki N, Takahashi C.

World J Stem Cells. 2016 Apr 26;8(4):170-84. doi: 10.4252/wjsc.v8.i4.170. Review.

18.

Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.

Horton JR, Engstrom A, Zoeller EL, Liu X, Shanks JR, Zhang X, Johns MA, Vertino PM, Fu H, Cheng X.

J Biol Chem. 2016 Feb 5;291(6):2631-46. doi: 10.1074/jbc.M115.698449. Epub 2015 Dec 8.

19.

Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.

Váraljai R, Islam AB, Beshiri ML, Rehman J, Lopez-Bigas N, Benevolenskaya EV.

Genes Dev. 2015 Sep 1;29(17):1817-34. doi: 10.1101/gad.264036.115. Epub 2015 Aug 27.

20.

Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.

Liu H, Liu L, Holowatyj A, Jiang Y, Yang ZQ.

Mol Carcinog. 2016 May;55(5):977-90. doi: 10.1002/mc.22341. Epub 2015 Jul 24.

Supplemental Content

Support Center